- Home
- BEAT vs RNXT Comparison
BEAT vs RNXT Comparison
Compare BEAT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- RNXT
- Stock Information
- Founded
- BEAT 2015
- RNXT 2012
- Country
- BEAT United States
- RNXT United States
- Employees
- BEAT N/A
- RNXT N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- BEAT Technology
- RNXT Health Care
- Exchange
- BEAT Nasdaq
- RNXT Nasdaq
- Market Cap
- BEAT 37.7M
- RNXT 44.6M
- IPO Year
- BEAT 2021
- RNXT 2021
- Fundamental
- Price
- BEAT $1.41
- RNXT $1.22
- Analyst Decision
- BEAT Buy
- RNXT Strong Buy
- Analyst Count
- BEAT 1
- RNXT 2
- Target Price
- BEAT $8.00
- RNXT $7.50
- AVG Volume (30 Days)
- BEAT 78.2K
- RNXT 646.9K
- Earning Date
- BEAT 11-06-2025
- RNXT 11-12-2025
- Dividend Yield
- BEAT N/A
- RNXT N/A
- EPS Growth
- BEAT N/A
- RNXT N/A
- EPS
- BEAT N/A
- RNXT N/A
- Revenue
- BEAT N/A
- RNXT $662,000.00
- Revenue This Year
- BEAT N/A
- RNXT $2,988.37
- Revenue Next Year
- BEAT $19.35
- RNXT $300.60
- P/E Ratio
- BEAT N/A
- RNXT N/A
- Revenue Growth
- BEAT N/A
- RNXT N/A
- 52 Week Low
- BEAT $0.91
- RNXT $0.75
- 52 Week High
- BEAT $3.48
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- BEAT 59.24
- RNXT 55.80
- Support Level
- BEAT $1.30
- RNXT $1.19
- Resistance Level
- BEAT $1.39
- RNXT $1.45
- Average True Range (ATR)
- BEAT 0.11
- RNXT 0.12
- MACD
- BEAT 0.01
- RNXT 0.02
- Stochastic Oscillator
- BEAT 61.05
- RNXT 54.90
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.